Shots: Merck will acquire all the outstanding shares of VelosBio for $2.75B in cash. The transaction is expected to be closed by the end of 2020 The acquisition will bolster […]readmore
Tags : Oncology Pipeline
Shots: AZ gains complete rights to monalizumab (Anti-NKG2A), also gains option rights to IPH5201 as well as 4 preclinical immuno-oncology molecules Innate gains US and EU rights of Lumoxiti approved […]readmore